Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
Buspirone
BUSPIRONE HCL · buspar · 8-[4-[4-(2-PYRIMIDINYL)-1-PIPERAZINYL]BUTYL]-8-AZASPIRO[4,5]DECANE-7,9-DIONE · Buspisal · Buspimen · BUSPIRONE · Nard：Tmvin · BUPROPIONHCL
식별자 및 물리적 특성
| CAS No. | 36505-84-7 |
|---|---|
| 분자식 | C21H31N5O2 |
| 평균 분자량 | 385.5 g/mol |
| 단동위원소 질량 | 385.24777523 g/mol |
| SMILES | O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1 |
| InChIKey | QWCRAEMEVRGPNT-UHFFFAOYSA-N |
| PubChem CID | 2477 |
| ChEMBL | CHEMBL49 |
| ChEBI | CHEBI:3223 |
| EC No. | 253-072-2 |
| DTXSID | DTXSID2022707 |
화학 및 물리적 성질
| XLogP | 2.6 |
|---|---|
| 극성 표면적 | 69.6 |
| 수소 결합 공여자 수 | 0 |
| 수소 결합 수용자 수 | 6 |
| 회전 가능 결합 수 | 6 |
| 무거운 원자 수 | 28 |
| 형식 전하 | 0 |
| 복잡도 | 529 |
| 의약품 | Pharmaceuticals -> Listed in ZINC15 |
| LogP(분배 계수) | 2.3 |
| 용해도 | 5.88e-01 g/L |
| Human Drugs | Breast FeedingLactationMilk, HumanAnti-Anxiety AgentsSerotonin AgonistsPharmaceuticals |
| 녹는점 | 201.5-202.5201.5 - 202.5 °C105-107 °C(Solv: ethyl acetate (141-78-6)) |
| Physical Description | Solid |
| Ionization Efficiency | Positive4.3347297742.7Thermo LTQElectrospray ionizationformic acid (5.3nM) |
| Dissociation Constants | 7.6 |
| Collision Cross Section | 196.8 Ų [M]+ [CCS Type: DTBuffer gas: N2Ionization: APCI+Dataset: TOXCASTSource Identifier: DTXSID2022707]195.97 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]199.3 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)] |
| 끓는 점 | 511.93°C (rough estimate) |
| 밀도 | 1.1527 (rough estimate) |
| 굴절률 | 1.7600 (estimate) |
| 저장 조건 | Sealed in dry,2-8°C |
| pKa(산도 계수) | pKa 7.60±0.01(H2O t=25.0 I=0.1(NaCl)) (Uncertain) |
| 물리적 상태 | Solid |
| 색상 | White to off-white |
| BCS Class | 1 |
| NIST | 8-Azaspiro[4.5]decane-7,9-dione, 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-(36505-84-7) |
| EPA | 8-Azaspiro[4.5]decane-7,9-dione, 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (36505-84-7) |
안전 및 규제
| GHS 분류 | DangerH301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 4 reports by companies from 1 notifications to the ECHA C&L Inventory. |
|---|---|
| 규제 정보 | Status: Active Update: 01-09-2020 https://echa.europa.eu/registration-dossier/-/registered-dossier/31319 |
| Hazard Classes and Categories | Acute Tox. 3 (100%) |
| Treatment | General symptomatic and supportive measures should be used along with immediate gastric lavage. Respiration, pulse, and blood pressure should be monitored as in all cases of drug overdosage. No specific antidote is known to buspirone, and dialyzability of buspirone has not been determined. (L1712) |
| Hepatotoxicity | Buspirone has been associated with infrequent serum aminotransferase elevations, but has not been linked to instances of clinically apparent liver injury in the published literature. Indeed, buspirone is often used as a control, noncytotoxic agent in assessment of other psychotropic drugs in vitro and in vivo. Buspirone is, nevertheless, metabolized in the liver by the P450 system (CYP 3A4) and has the potential of causing drug-drug interactions. |
| 유해 작용 | Dizziness is a common side effect that occurs in over 10% of patients. |
| 노출 경로 | Oral. Rapidly absorbed in man. Bioavailability is low and variable (approximately 5%) due to extensive first pass metabolism. |
| 독성 요약 | Relative to other anxiolytics, buspirone has low toxicity and potential for abuse. There have been no deaths reported from a buspirone overdose alone. In pharmacological trials, healthy male patients were given up to 375 mg daily and developed nausea, vomiting, dizziness, drowsiness, miosis, and gastric distress. While buspirone overdose typically resolves with complete recovery, high suspicion of other medication overdoses should be maintained and investigated. In a literature review, multiple reports of movement disorders, including dyskinesia, akathisia, myoclonus, parkinsonism, and dystonia, have been reported.Buspirone binds to 5-HT type 1A serotonin receptors on presynaptic neurons in the dorsal raphe and on postsynaptic neurons in the hippocampus, thus inhibiting the firing rate of 5-HT-containing neurons in the dorsal raphe. Buspirone also binds at dopamine type 2 (DA2) receptors, blocking presynaptic dopamine receptors. Buspirone increases firing in the locus ceruleus, an area of brain where norepinephrine cell bodies are found in high concentration. The net result of buspirone actions is that serotonergic activity is suppressed while noradrenergic and dopaminergic cell firing is enhanced. |
| Signs and Symptoms | Symptoms of overdose include dizziness, drowsiness, nausea or vomiting, severe stomach upset, and unusually small pupils. |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Drug Induced Liver Injury | Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)buspironeBuSpar®Anxiolytics3less-DILI-concern drugs |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| Toxicity Data | LD50: 136 mg/kg (Oral, rat) |
| 수질 위해 등급(WGK) | 3 |
| RTECS 번호 | CL9915000 |
| 운송 번호(UN) | UN 2811 6.1/PG 3 |
| 위험 문구(R) | 25 |
| 위험 표시 | T |
| 안전 문구(S) | 45 |
용도
용도
Buspirone is an extremely specific drug that could possibly represent a new chemical class of anxiolytics—azaspirones. As an anxiolytic, its activity is equal to that of benzodiazepines; however, it is devoid of anticonvulsant and muscle relaxant properties, which are characteristic of benzodiazepines.
일반 설명
The initial compound in this series, buspirone (BuSpar), hasanxiolytic and antidepressant activities and is a partial5-HT1A agonist. Its anxiolytic activity is reportedly causedby its ability to diminish 5-HT release (via 5-HT1A agonism).High short-term synaptic levels of 5-HT are characteristic ofanxiety. Also, because it is a partial agonist, it can stimulatepostsynaptic receptors when 5-HT levels are low in thesynapse, as is the case in depression. Several other spironesare in development as anxiolytics and antidepressants.